SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Paul Robeson

PatientPaul Robeson
Date of birth1967-04-09
IdentifiersMRN HR-ML048-SYN; SSN (made up) 000-48-2647
Document date2026-08-24
AuthorTheodore Bankole-Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twenty-four-week review of depression treatment. [S]

History of Present Illness

Mr. Robeson returns eleven weeks after the switch to venlafaxine; he has taken 225 mg each morning for seven weeks. He sleeps five and a half hours, walks every morning, and has begun to read and see one or two old friends, but he still has little pleasure in music and has not sung in public. The cough from four weeks ago has gone. He sweats a little more than before. He has had no thoughts of suicide since the spring and no elation. He has completed sixteen behavioral activation sessions and continues fortnightly with his psychologist, who reports PHQ-9 scores in the low to mid teens. He asked what else can be done, including whether he would need shock treatment. [S]

ElementDetail
MedicinesVenlafaxine 225 mg for seven weeks, eleven weeks in all
MoodPHQ-9 13 from 22: partial response
Side effectsMild sweating; blood pressure 134/84
QuestionWhat else can be done, including ECT

Review of Systems

SystemResultFinding
ConstitutionalPositiveMild sweating; weight 101.0 kg
PsychiatricPositiveLow mood on most days, little pleasure in music; no thoughts of suicide; no elation
RespiratoryNegativeCough gone
CardiovascularNegativeNo palpitations or headache
NeurologicalNegativeNo memory complaint or tremor

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg tablet, one tablet each morning50 mg each morning for two weeksOral route2026-03-12 to 2026-03-25completedS
Sertraline 100 mg tablet, one tablet each morning100 mg each morningOral route2026-03-26 to 2026-04-19completedS
Sertraline 50 mg tablets, three tablets (150 mg) each morning150 mg each morning for two weeksOral route2026-04-20 to 2026-05-03completedS
Sertraline 100 mg tablets, two tablets (200 mg) each morning200 mg each morningOral route2026-05-04 to 2026-06-07completedS
Sertraline 100 mg tablet, one tablet each morning for one week, then stop100 mg each morning for one week during the switchOral route2026-06-08 to 2026-06-14completedS
Venlafaxine extended-release 75 mg capsule, one capsule each morning with food75 mg each morning for one weekOral route2026-06-08 to 2026-06-14completedS
Venlafaxine extended-release 150 mg capsule, one capsule each morning with food150 mg each morning for three weeksOral route2026-06-15 to 2026-07-05completedS
Venlafaxine extended-release 75 mg capsules, three capsules (225 mg) each morning with food225 mg each morning; 30-day supply at a timeOral route2026-07-06activeS
Aripiprazole 2 mg tablet, one tablet each morning2 mg each morning for two weeksOral route2026-08-24 to 2026-09-06completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-24Body height190cmS
2026-08-24Body weight101kgS
2026-08-24Body mass index (BMI) [Ratio]28kg/m2S
2026-08-24Systolic blood pressure134mm[Hg]S
2026-08-24Diastolic blood pressure84mm[Hg]S
2026-08-24Heart rate78/minS
2026-08-24Respiratory rate14/minS
2026-08-24Body temperature36.6CelS
2026-08-24Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-24Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
2026-08-24Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-08-24Hemoglobin A1c/Hemoglobin.total in Blood5.6%Below 5.7% is normal; 5.7 to 6.4% prediabetesNormalS
2026-08-24Cholesterol [Mass/volume] in Serum or Plasma204mg/dL<=199 mg/dLHighS
2026-08-24Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=40 mg/dLNormalS
2026-08-24Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
2026-08-24Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation132mg/dL<=129 mg/dLHighS
2026-08-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]13{score}S
2026-08-24Total score [MoCA]28{score}S

Physical Exam

Vital signs recorded on 2026-08-24; see the Vital Signs section. [S]

SystemFinding
GeneralWeight 101.0 kg, BMI 28.0; blood pressure 134/84, pulse 78
NeurologicalNo tremor, rigidity or abnormal movements; abnormal involuntary movement examination normal
PsychiatricLess slowed; affect a little fuller; logical; no thoughts of suicide

Problems

ProblemClinical statusVerificationCodeProvenance
About three months of low mood, exhaustion, poor sleep with waking at three in the morning, loss of interest in singing and reading, poor appetite with 5 kg weight loss, and withdrawal from friends, in a man of 58 under sustained political pressure; PHQ-9 22 with thoughts of being better off dead; depression suspected; medical causes being excluded and urgent psychiatric consultation arrangedresolvedconfirmed R53.83S — Synthetic presenting problem at intake, superseded by the diagnosis at the psychiatric consultation; anchored to his documented depression and loss of work (D).
Major depressive disorder, recurrent, severe, without psychotic features (second episode; structured diagnostic interview; MDQ negative and no past hypomanic or manic episode on interview)activeconfirmed F33.2S — Synthetic modern diagnosis anchored to his documented depression after the 1955 breakdown (D); the bipolar interpretation (R) is addressed and not adopted.
Sustained political persecution: passport withheld, concerts and recordings cancelled, income lost, and surveillance by federal agencies; a major and realistic stressor, not a delusionactiveconfirmed Z60.5S — Synthetic coding of his documented persecution as a social determinant of his depression.
Acute bronchitis after a cold, without signs of pneumonia; treated without antibiotics and without dextromethorphan or decongestants because of venlafaxine; resolvedresolvedconfirmed J20.9S — Synthetic intercurrent illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline and at least monthly during acute treatment (CMID)Completed today13, down 41 percent from 22: partial response; item 9 scored 0
SurveyPHQ-9 between visits, rated by the psychologist at each sessionAt each therapy sessionCompleted todayRated at each session; no positive item 9 reported
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, locked medicines and the 988 Suicide & Crisis LifelineEvery visit during active treatmentCompleted todayNo thoughts of suicide since the spring; medicines locked; safety plan reviewed
LaboratorySodium (SSRI or SNRI in an older adult)Baseline, about four to six weeks after starting, and with symptomsCompleted today136 mmol/L, normal
Medication safetyBlood pressure (venlafaxine)Baseline and at every visit on venlafaxineCompleted today134/84, up slightly from 128/80; recheck at each visit
Medication safetyAdequacy of the antidepressant trial (dose and duration)At each review: at least four to eight weeks at an adequate dose before judging responseCompleted todaySecond adequate trial (seven weeks at 225 mg): partial response; treatment-resistant
Medication safetyAdherence and adverse-effect reviewEvery visitCompleted todayEvery dose taken; mild sweating
Medication safetyWatch for hypomania or mixed features after starting or changing an antidepressantEvery visit; repeat the MDQ if features emergeCompleted todayNo signs of hypomania
SurveyCognitive screen (MoCA)Baseline, and before and during any course of ECTCompleted today28, unchanged; kept as a baseline in case ECT is chosen later
Medication safetyECT informed consent discussion and alternatives (rTMS, esketamine)When depression is treatment-resistant or severeCompleted todayDiscussed; ECT not started now by his choice and because there is no urgent indication; available on equal terms if augmentation fails
Self-managementWeight and BMI on aripiprazoleBaseline, 4, 8 and 12 weeks, then quarterly (CMID)Completed todayBaseline 101.0 kg, BMI 28.0 before aripiprazole
LaboratoryHemoglobin A1c or fasting glucose, and lipids, on aripiprazoleBaseline, 12 weeks, then yearly (CMID)Completed todayA1c 5.6%, glucose 94 mg/dL; total cholesterol 204, HDL 46, triglycerides 130, LDL 132 mg/dL
ExaminationAbnormal Involuntary Movement ScaleBaseline, then every six months on an antipsychotic (CMID)Completed todayBaseline examination normal
ReferralBehavioral activation with a psychologistWeekly for sixteen sessions, then fortnightlyCompleted todaySixteen sessions completed; fortnightly sessions continue
ReferralSocial work for income and costsMonthlyCompleted todayMonthly meetings continue

Goal progress:

Guideline basis: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 2nd edition (record of the American Journal of Psychiatry review, 2002) (2001); The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. A Task Force Report of the American Psychiatric Association, 3rd edition (Library of Congress catalog record, LCCN 2024014438) (2024); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Williams DR, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 2007;64(3):305-315 (2007); Sprenger S, et al. Retrospective Cohort Study of Racial-Ethnic Disparities in Receipt of Electroconvulsive Therapy, 2016-2021. Psychiatr Serv 2025;76(8):736-740 (2025)

Follow-up: Nurse phone check in two weeks before the aripiprazole increase. Preventive visit in six weeks with the PHQ-9 and weight. Twelve-week metabolic tests. Call or text 988 at any time in a crisis. Next scheduled visit 2026-10-05: periodic adult preventive visit. [S]